CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 106 enrolled
Drug / intervention
FF-10502-01drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02661542
NCT02661542Phase 2Completed
CompareCT.gov

A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas

Fujifilm Pharmaceuticals U.S.A., Inc.·interventional·Posted Jan 22, 2016·Updated Apr 23, 2026

In Brief

A Phase 2 clinical trial evaluating FF-10502-01 for Solid Tumors and Lymphomas. Completed, enrolled 106 participants across 2 sites.

Detailed Summary

A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and Lymphomas. A total of up to 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD). Phase 2 will consist of 2 cohorts: Cohort 1 will include subjects with Pancreatic Cancer. Cohort 2 will include subjects with another tumor type enrolled in the Phase 1 dose-escalation phase who have demonstrated Clinical Benefit by Week 16.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors, Lymphomas
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 22, 2016
Enrollment StartJan 1, 2016
Primary CompletionNov 5, 2020
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 10.4 years ago

Interventions

FF-10502-01drug